HIV Prevention

Phase I testing of HIV microbicide initiated

Published in Women's Health Weekly, October 2nd, 2003

Biosyn, Inc., announced that enrollment has been initiated for a phase I clinical trial for the investigational drug candidate, UC-781, as a microbicide for the prevention of sexually transmitted HIV.

UC-781 is an HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) that has shown in vitro to be very active specifically against HIV-1.

This first clinical trial of UC-781 is a single-center, phase I, placebo-controlled, closed-label, randomized study to evaluate the safety and acceptability of daily intravaginal dosing of the product among 48 healthy sexually abstinent women. Participants will be administering 3.5 ml of 0.1%, 0.25%, 1.0% UC-781...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-10-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry